Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

University of Aarhus

Status: Completed

Conditions: Non-small Cell Lung Cancer Patients

Treatments: Procedure: 18F-FDG-PET scan

Study type: Interventional

Funder types: Other

Identifiers

NCT02043002

Thomas

Details and patient eligibility

About

Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking.

Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.

Enrollment: 67 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lung Cancer patients with non-small cell histology and stage IV disease
• candidate for erlotinib treatment as first/ second/ third line of treatment

Exclusion criteria

• pregnancy
• severe dyspnoea

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

67 participants in 1 patient group

18F-FDG-PET scan

Experimental group

Description:

An early evaluation 18F-FDG-PET scan after 7-10 days

Treatment:

Procedure: 18F-FDG-PET scan